NeoGenomics Reports Q1 2025 Earnings with Revenue Growth and EBITDA Expansion
NeoGenomics (NEO) reported Q1 2025 earnings with total revenue of $168 million, up 8% year over year, and adjusted EBITDA of $7.1 million, representing over 100% growth compared to the prior year. The company also noted an 8% increase in clinical testing volume and a 22% contribution from five new NGS products.
Topics: Acquisition Impact Clinical Testing Earnings Revenue Growth